Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 2, 2008, Pages 365-370

  Chin, Judy N ^a   Jones, Ronald N ^b   Sader, Helio S ^b   Savage, Paul B ^c   Rybak, Michael J ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b JMI LABORATORIES   (United States)

^c Brigham Young University   (United States)

Author keywords

Cationic steroid antimicrobial; Gram negative; Resistance

Indexed keywords

ANTIINFECTIVE AGENT; CEFEPIME; CERAGENIN; CIPROFLOXACIN; CSA 13; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DILUTION; DRUG ANTAGONISM; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; STRAIN DIFFERENCE; TIME;

EID: 38349170070     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm457     Document Type: Article

References (25)

1. Crespo MP, Woodford N, Sinclair A et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-β-lactamase, in a tertiary care center in Cali, Colombia. J Clin Microbiol 2004; 42: 5094-101.
2. Kirby JT, Fritsche TR, Jones RN. Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients: Report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America). Diagn Microbiol Infect Dis 2006; 56: 75-82.
3. Meyer E, Schwab F, Gastmeier P et al. Surveillance of antimicrobial use and antimicrobial resistance in German intensive care units (SARI): A summary of the data from 2001 through 2004. Infection 2006; 34: 303-9.
4. Nouér SA, Nucci M, de-Oliveira MP et al. Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-β-lactamase. Antimicrob Agents Chemother 2005; 49: 3663-7.
5. Sader HS, Castanheira. M, Mendes RE et al. Dissemination and diversity of metallo-β-lactamases in Latin America: Report from the SENTRY Antimicrobial Surveillance Program. Int J Antimicrob Agents 2005; 25: 57-61.
6. Yamaguchi K, Mathai D, Biedenbach DJ et al. Evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents tested against over 2000 clinical isolates from 22 medical centers in Japan. Diagn Microbiol Infect Dis 1999; 34: 123-34.
7. Aloush V, Navon-Venezia S, Seigman-Igra Y et al. Multidrug-resistant Pseudomonas aeruginosa: Risk factors and clinical impact. Antimicrob Agents Chemother 2006; 50: 43-8.
8. Giamarellos-Bourboulis EJ, Papadimitriou E, Galanakis N et al. Multidrug resistance to antimicrobials as a predominant factor influencing patient survival. Int J Antimicrob Agents 2006; 27 476-81.
9. Lautenbach E, Weiner MG, Nachamkin I et al. Imipenem resistance among Pseudomonas aeruginosa isolates: Risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006; 27: 893-900.
10. Savage PB, Li C, Taotafa U et al. Antibacterial properties of cationic steroid antibiotics: A minireview. FEMS Microbiol Lett 2002; 217: 1-7.
11. Van 't Hof W, Veerman EC, Helmerhorst EJ et al. Antimicrobial peptides: Properties and applicability. Biol Chem 2001; 382: 597-619.
12. Guan Q, Schmidt EJ, Boswell SR et al. Preparation and characterization of cholic acid-derived antimicrobial agents with controlled stabilities. Org Lett 2000; 2: 2837-40.
13. Li C, Budge LP, Driscoll CD et al. Incremental conversion of outer-membrane permeabilizers into potent antibiotics for Gram-negative bacteria. J Am Chem Soc 1999; 121: 931-40.
14. Li C, Peters AS, Meredith EL et al. Design and synthesis of potent sensitizers of Gram-negative bacteria based on a cholic acid scaffolding. J Am Chem Soc 1998; 120: 2961-2.
15. Ding B, Guan Q, Walsh JP et al. Correlation of the antibacterial activities of cationic peptide antibiotics and cationic steroid antibiotics. J Med Chem 2002; 45: 663-9.
16. Kikuchi K, Bernard EM, Sadownik A et al. Antimicrobial activities of squalamine mimics. Antimicrob Agents Chemother 1997; 41: 1433-8.
17. Li C, Lewis MR, Gilbert AB et al. Antimicrobial activities of amine- and guanidine-functionalized cholic acid derivatives. Antimicrob Agents Chemother 1999; 43: 1347-51.
18. Chin JN, Rybak W, Cheung CM et al. Antimicrobial activities of ceragenins against clinical isolates of resistant Staphytococcus aureus. Antimicrob Agents Chemother 2007; 51: 1268-73.
19. Savage PB, Chambers HF, Genberg C et al. Activity of a novel cationic steroid antimicrobial (CSA-13) targeting aerobic and facultative Gram-negative bacilli, Gram-positive anaerobes and select agent surrogate strains. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract F-1231. American Society for Microbiology, Washington, DC, USA.
20. Savage PB, Chambers HF, Genberg C et al. Activity of a novel cationic steroid antimicrobial (CSA-13) against Staphylococcus aureus and bacterial species associated with infections in cystic fibrosis patients. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA, 2005. Abstract F-1232. American Society for Microbiology, Washington, DC, USA.
21. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement CLSI document M7-A7. CLSI, Wayne, PA, USA, 2006.
22. Epand RF, Savage PB, Epand RM. Bacterial lipid composition and the antimicrobial efficacy of cationic steroid compounds (ceragenins). Biochim Biophys Acta 2007; 1768: 2500-9.
23. Owens RC Jr, Banevicius MA, Nicolau DP et al. In vitro synergistic activities of tobramycin and selected β-lactams against 75 gram-negative clinical isolates. Antimicrob Agents Chemother 1997; 41: 2586-8.
24. Tam VH, Schilling AN, Lewis RE et al. Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. Antimicrob Agents Chemother 2004; 48: 4315-21.
25. Savage PB, Orsak T, Burns JL. A cationic steroid antibiotic active against highly tobramycin-resistant Pseudomonas aeruginosa. In: Abstracts of the 2005 Annual Conference on Antimicrobial Resistance, Bethesda, MD, 2005. Abstract P12. National Foundation for Infectious Diseases, Bethesda, MD, USA.